Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
HUTCHMED (China) Limited HCM
$13.45
-$0.57 (-4.20%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
2576863430.00000000
-
week52high
21.28
-
week52low
7.39
-
Revenue
426409000
-
P/E TTM
-7
-
Beta
0.82480900
-
EPS
-2.09000000
-
Last Dividend
0.00000000
-
Next Earnings Date
23 мая 2023 г. в 04:00
Описание компании
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Neutral | Neutral | 09 авг 2022 г. |
| Goldman Sachs | Neutral | Neutral | 02 авг 2022 г. |
| Goldman Sachs | Neutral | Buy | 22 сент 2021 г. |
| Jefferies | Buy | 03 авг 2021 г. | |
| Cantor Fitzgerald | Overweight | 13 мар 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Wall Street Analysts See a 103.84% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
Zacks Investment Research
26 апр 2023 г. в 11:28
The consensus price target hints at a 103.8% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
All You Need to Know About HUTCHMED (HCM) Rating Upgrade to Buy
Zacks Investment Research
10 апр 2023 г. в 13:41
HUTCHMED (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think HUTCHMED (HCM) Could Surge 102.73%: Read This Before Placing a Bet
Zacks Investment Research
10 апр 2023 г. в 11:23
The consensus price target hints at a 102.7% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
HUTCHMED to Announce 2022 Final Results
GlobeNewsWire
31 янв 2023 г. в 03:30
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2022 on Tuesday, February 28, 2023 at 3:30 am Eastern Standard Time (EST) / 8:30 am Greenwich Mean Time (GMT) / 4:30 pm Hong Kong Time (HKT).
Does HUTCHMED (HCM) Have the Potential to Rally 68.08% as Wall Street Analysts Expect?
Zacks Investment Research
25 янв 2023 г. в 11:18
The mean of analysts' price targets for HUTCHMED (HCM) points to a 68.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.